Dogwood Therapeutics (NASDAQ:DWTX) Stock Price Down 5.9% – Time to Sell?

Dogwood Therapeutics, Inc (NASDAQ:DWTX)’s share price was down 5.9% during trading on Wednesday. The stock traded as low as $1.43 and last traded at $1.43. 50,285 shares changed hands during mid-day trading, a decline of 25% from the average daily volume of 66,661 shares. The stock had previously closed at $1.52.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dogwood Therapeutics has an average rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Performance

The stock has a market cap of $47.59 million, a price-to-earnings ratio of -0.16 and a beta of 1.92. The company’s 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $1.75.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.20). On average, equities research analysts predict that Dogwood Therapeutics, Inc will post -0.8 earnings per share for the current fiscal year.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression.

Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID.

The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development.